within Pharmacolibrary.Drugs.ATC.L;

model L01XX35
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011833333333333333,
    Tlag           = 600,            
    Vdp             = 0.14,
    k12             = 62,
    k21             = 62
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX35</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor used for the treatment of essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombosis. It is approved and utilized clinically for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adults and patients with essential thrombocythemia after oral administration.</p><h4>References</h4><ol><li><p>Petrides, PE, et al., &amp; Klade, CS (2018). Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product. <i>Clinical pharmacology in drug development</i> 7(2) 123–131. DOI:<a href=\"https://doi.org/10.1002/cpdd.340\">10.1002/cpdd.340</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28301098/\">https://pubmed.ncbi.nlm.nih.gov/28301098</a></p></li><li><p>Pescatore, SL, &amp; Lindley, C (2000). Anagrelide: a novel agent for the treatment of myeloproliferative disorders. <i>Expert opinion on pharmacotherapy</i> 1(3) 537–546. DOI:<a href=\"https://doi.org/10.1517/14656566.1.3.537\">10.1517/14656566.1.3.537</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11249536/\">https://pubmed.ncbi.nlm.nih.gov/11249536</a></p></li><li><p>Toivanen, K, et al., &amp; Sihto, H (2025). Pharmacokinetic profile and . <i>Drug delivery</i> 32(1) 2463433–None. DOI:<a href=\"https://doi.org/10.1080/10717544.2025.2463433\">10.1080/10717544.2025.2463433</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39930717/\">https://pubmed.ncbi.nlm.nih.gov/39930717</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX35;
